Article
Licensed
Unlicensed Requires Authentication

Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies

  • , , , , , , and
Published/Copyright: September 21, 2011
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 44 Issue 2

Abstract

The intra vitam diagnosis of different dementias is still based on clinical grounds. So far, no technical investigations have been available to support these diagnoses. For tau protein and β-amyloid(1–42) in cere-brospinal fluid (CSF), promising results for the diagnosis of Alzheimer's disease (AD) have been reported; however, their differential diagnostic spectrum is limited, as was recently shown for dementia with Lewy bodies (DLB) and for AD. Therefore, further marker proteins have to be established to ameliorate, support, and differentiate these clinical diagnoses. We evaluated β-amyloid(1–40) and phosphorylated tau protein (181p), in addition to total tau protein and β-amyloid(1–42), in 20 patients with DLB, 34 AD patients, and 20 non-demented neurological controls (NDCs). All markers could differentiate between the dementia groups (AD, DLB) and the controls. AD and DLB could be differentiated only by levels of total tau protein and by the ratio total tau protein/phosphorylated tau protein. However, values still overlapped markedly. In some cases, tau protein levels in CSF may contribute to the clinical distinction between DLB and AD, but the value of the markers is still limited, especially because of mixed pathology. We conclude that more specific markers have to be established to differentiate between these diseases.

Keywords: Alzheimer's disease; β-amyloid; cerebrospinal fluid; dementia with Lewy bodies; laboratory marker; phosphorylated tau protein; total tau protein
Corresponding author: Brit Mollenhauer, MD, Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, 77, Avenue Louis Pasteur, Harvard Institutes of Medicine (HIM) 764, Boston, MA 02115, USA Phone: +1-617-525-5123, Fax: +1-617-525-5305,

References

1. McKeith IG, Galasko D, Kosaka, Perry EK, Dickson DW, Hansen L, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy-bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113–24.10.1212/WNL.47.5.1113Search in Google Scholar

2. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased β-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. J Am Med Assoc 2003; 289:2094–103.10.1001/jama.289.16.2094Search in Google Scholar

3. Gomez-Tostosa E, Gonzales I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 2003; 60:1218–22.Search in Google Scholar

4. Tschampa H, Schulz-Schaeffer WJ, Wiltfang J, Poser S, Otto M, Neumann N, et al. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology 2001; 56:576.10.1212/WNL.56.4.576Search in Google Scholar

5. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, et al. Tau protein, Aβ42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005; 19:164–70.10.1159/000083178Search in Google Scholar

6. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Steinacker P, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J Neural Transm 2005; 112:933–48.10.1007/s00702-004-0235-7Search in Google Scholar

7. Harrington CR, Perry RH, Perry EK, Hurt J, McKeith IG, Roth M, et al. Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia 1994; 5:215–22.Search in Google Scholar

8. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F, et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 2001; 22:77–8.10.1007/s100720170055Search in Google Scholar

9. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer's disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59:1267–72.10.1001/archneur.59.8.1267Search in Google Scholar

10. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD-patients using β-amyloid(1–42) and tau levels in CSF. Neurology 1999; 52:1555–62.10.1212/WNL.52.8.1555Search in Google Scholar

11. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiol Aging 2004; 25:273–81.10.1016/S0197-4580(03)00086-1Search in Google Scholar

12. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998; 44:17–26.10.1002/ana.410440108Search in Google Scholar PubMed

13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939–44.10.1212/WNL.34.7.939Search in Google Scholar

14. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in differential diagnosis of Alzheimer's disease. Arch Gen Psychiatry 2004; 61:95–102.10.1001/archpsyc.61.1.95Search in Google Scholar PubMed

Received: 2005-8-17
Accepted: 2005-11-15
Published Online: 2011-9-21
Published in Print: 2006-2-1

©2006 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Allergy testing: the role of recombinant allergens
  2. Autoimmune diagnostics in diabetes mellitus
  3. Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis
  4. Autoimmune bullous disorders
  5. Laboratory network of excellence: enhancing patient safety and service effectiveness
  6. Novel mutations in the 5′-UTR of the FOLR1 gene
  7. CYP2C8 polymorphism among the Portuguese
  8. Actual levels of soy phytoestrogens in children correlate with thyroid laboratory parameters
  9. Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer
  10. Comparison of Brucella immunoglobulin M and G flow assays with serum agglutination and 2-mercaptoethanol tests in the diagnosis of brucellosis
  11. Experimental and computer modelling speciation studies of the effect of pH and phosphate on the precipitation of calcium and magnesium salts in urine
  12. Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies
  13. Establishment of an indocyanine green test using an automatic chemistry analyzer
  14. Relationship between serum sialic acids, sialic acid-rich inflammation-sensitive proteins and cell damage in patients with acute myocardial infarction
  15. Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease
  16. Nitration of human plasminogen by RAW 264.7 macrophages reduces streptokinase-induced plasmin activity
  17. Comparison of triglyceride concentration with lipemic index in disorders of triglyceride and glycerol metabolism
  18. Measurement of glycated hemoglobin (HbA1c) with an automated POCT instrument in comparison with HPLC and automated immunochemistry method: evaluation of the influence of hemoglobin variants
  19. Analytical performance and clinical efficacy for cardiovascular risk estimation of an Olympus immunoturbidimetric high-sensitivity C-reactive protein assay
  20. Systemic matrix metalloproteinase-9 (MMP-9) levels as prognostic indexes of bone disease in patients with multiple myeloma
  21. Systemic levels of matrix metalloproteinase-9 in patients with multiple myeloma may be useful as a prognostic index of bone disease. Reply to the Letter by Demacq and Montenegro
  22. Society of Medical Biochemists of Serbia and Montenegro: 50-year anniversary
https://doi.org/10.1515/CCLM.2006.035
Keywords for this article
Alzheimer's disease; β-amyloid; cerebrospinal fluid; dementia with Lewy bodies; laboratory marker; phosphorylated tau protein; total tau protein

Articles in the same Issue

  1. Allergy testing: the role of recombinant allergens
  2. Autoimmune diagnostics in diabetes mellitus
  3. Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis
  4. Autoimmune bullous disorders
  5. Laboratory network of excellence: enhancing patient safety and service effectiveness
  6. Novel mutations in the 5′-UTR of the FOLR1 gene
  7. CYP2C8 polymorphism among the Portuguese
  8. Actual levels of soy phytoestrogens in children correlate with thyroid laboratory parameters
  9. Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer
  10. Comparison of Brucella immunoglobulin M and G flow assays with serum agglutination and 2-mercaptoethanol tests in the diagnosis of brucellosis
  11. Experimental and computer modelling speciation studies of the effect of pH and phosphate on the precipitation of calcium and magnesium salts in urine
  12. Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies
  13. Establishment of an indocyanine green test using an automatic chemistry analyzer
  14. Relationship between serum sialic acids, sialic acid-rich inflammation-sensitive proteins and cell damage in patients with acute myocardial infarction
  15. Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease
  16. Nitration of human plasminogen by RAW 264.7 macrophages reduces streptokinase-induced plasmin activity
  17. Comparison of triglyceride concentration with lipemic index in disorders of triglyceride and glycerol metabolism
  18. Measurement of glycated hemoglobin (HbA1c) with an automated POCT instrument in comparison with HPLC and automated immunochemistry method: evaluation of the influence of hemoglobin variants
  19. Analytical performance and clinical efficacy for cardiovascular risk estimation of an Olympus immunoturbidimetric high-sensitivity C-reactive protein assay
  20. Systemic matrix metalloproteinase-9 (MMP-9) levels as prognostic indexes of bone disease in patients with multiple myeloma
  21. Systemic levels of matrix metalloproteinase-9 in patients with multiple myeloma may be useful as a prognostic index of bone disease. Reply to the Letter by Demacq and Montenegro
  22. Society of Medical Biochemists of Serbia and Montenegro: 50-year anniversary
Downloaded on 7.4.2026 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2006.035/html
Scroll to top button